Mydecine Innovations Group (Mydecine Innovations Group) Minority Interest : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Mydecine Innovations Group's minority interest for the quarter that ended in Sep. 2023 was $0.00 Mil.

Mydecine Innovations Group Minority Interest Historical Data

The historical data trend for Mydecine Innovations Group's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Minority Interest Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Minority Interest

Get a 7-Day Free Trial

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Mydecine Innovations Group Minority Interest Calculation

Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

MYIG:UK 0NF0:Germany MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.